<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6 ADVERSE REACTIONS<BR>               <BR>                  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           <BR>                               Most frequent (all causalities, incidence ≥ 2%): visual disturbances, fever, nausea, rash, vomiting, chills, headache, liver function test abnormal, tachycardia, hallucinations (6)<BR>                           <BR>                               <BR>                              To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.<BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.1 Overview<BR>                     <BR>                        The most frequently reported adverse events (all causalities) in the therapeutic trials were visual disturbances (18.7%), fever (5.7%), nausea (5.4%), rash (5.3%), vomiting (4.4%), chills (3.7%), headache (3.0%), liver function test increased (2.7%), tachycardia (2.4%), hallucinations (2.4%). The treatment-related adverse events which most often led to discontinuation of voriconazole therapy were elevated liver function tests, rash and visual disturbances [see Warning and Precautions (5.2, 5.3)<BR>                           <BR>                            and <BR>                           <BR>                              Adverse Reactions (6.2<BR>                           <BR>                           <BR>                              , 6.3)<BR>                           ].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.2 Clinical Trial Experience in Adults<BR>                     <BR>                        The data described in Table 2 reflect exposure to voriconazole in 1,655 patients in the therapeutic studies. This represents a heterogeneous population, including immunocompromised patients, e.g., patients with hematological malignancy or HIV and non-neutropenic patients. This subgroup does not include healthy subjects and patients treated in the compassionate use and non-therapeutic studies. This patient population was 62% male, had a mean age of 46 years (range 11 to 90, including 51 patients aged 12 to 18 years) and was 78% white and 10% black. Five hundred sixty one patients had a duration of voriconazole therapy of greater than 12 weeks, with 136 patients receiving voriconazole for over 6 months. Table 2 includes all adverse events which were reported at an incidence of ≥ 2% during voriconazole therapy in the all therapeutic studies population, studies 307/602 and 608 combined or study 305, as well as events of concern which occurred at an incidence of < 2%.<BR>                        In study 307/602, 381 patients (196 on voriconazole, 185 on amphotericin B) were treated to compare voriconazole to amphotericin B followed by other licensed antifungal therapy in the primary treatment of patients with acute invasive aspergillosis. The rate of discontinuation from voriconazole study medication due to adverse events was 21.4% (42/196 patients). In study 608, 403 patients with candidemia were treated to compare voriconazole (272 patients) to the regimen of amphotericin B followed by fluconazole (131 patients). The rate of discontinuation from voriconazole study medication due to adverse events was 19.5% out of 272 patients. Study 305 evaluated the effects of oral voriconazole (200 patients) and oral fluconazole (191 patients) in the treatment of esophageal candidiasis. The rate of discontinuation from voriconazole study medication in Study 305 due to adverse events was 7% (14/200 patients). Laboratory test abnormalities for these studies are discussed under Clinical Laboratory Values below.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="767.000" ID="id_bf097cff-7a76-4b85-8c89-8b85c01f5054"><BR>                           <caption ID="id_94ee7e35-2de3-4a10-8418-719dc7970a61">Table 2. Treatment Emergent Adverse Events Rate &#8805; 2% on Voriconazole or Adverse Events of Concern in All Therapeutic Studies Population, Studies 307/602-608 Combined or Study 305. Possibly Related to Therapy or Causality Unknown<footnote ID="id-6e05bc1b-60e8-48b2-99b5-a47a36a69f54"><BR>                                 <content styleCode="bold">Study 307/602: invasive aspergillosis; Study 608: candidemia; Study 305: esophageal candidiasis</content><BR>                              </footnote><BR>                           </caption><BR>                           <col width="15.5%"/><BR>                           <col width="13.3%"/><BR>                           <col width="14.5%"/><BR>                           <col width="14.5%"/><BR>                           <col width="13.3%"/><BR>                           <col width="14.5%"/><BR>                           <col width="14.5%"/><BR>                           <tbody><BR>                              <tr ID="id_02f7a616-2d25-4868-8a4a-a4b123dd1fb6"><BR>                                 <td align="left" valign="top" rowspan="2" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">All Therapeutic Studies</content><BR>                                 </td><BR>                                 <td align="center" valign="top" colspan="3" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Studies 307/602 and 608 </content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(IV/oral therapy) </content><BR>                                 </td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Study 305 </content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(oral therapy) </content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_23c55850-ec74-48cd-8845-a5f92452206e"><BR>                                 <td align="center" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph>Voriconazole</paragraph>n = 1,655 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>Voriconazole</paragraph>n = 468 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>Ampho B<footnote ID="id-6d33aae3-cac4-4f0e-a9b6-582c7969260c">Amphotericin B followed by other licensed antifungal therapy</footnote><BR>                                    </paragraph>n = 185 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>Ampho B&#8594;</paragraph><BR>                                    <paragraph>Fluconazole</paragraph>n = 131 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>Voriconazole</paragraph>n = 200 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>Fluconazole</paragraph>n = 191 </td><BR>                              </tr><BR>                              <tr ID="id_d1af9297-1176-48b5-84f3-ffcad286e08e"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">n (%) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">n (%) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">n (%) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">n (%) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">n (%) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">n (%) </td><BR>                              </tr><BR>                              <tr ID="id_9bcd2250-22da-4709-b7ef-000e8edb793b"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Special Senses<footnote ID="id-e4137e37-dfdc-4efc-8386-22c17c546b12">See <linkHtml href="#i4i_section_id_d35c4adf-eeb8-44cf-8441-d41a2ecbc883">Warnings and Precautions (5.3)</linkHtml><BR>                                       </footnote><BR>                                    </content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_ad0067cc-7a9c-452a-afbf-e7b984a404bf"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Abnormal vision </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">310 (18.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">63 (13.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">31 (15.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (4.2) </td><BR>                              </tr><BR>                              <tr ID="id_f94d5d23-badd-4cec-b48c-851a160c2abf"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Photophobia </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">37 (2.2) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (1.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">5 (2.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1) </td><BR>                              </tr><BR>                              <tr ID="id_8c258fab-0385-4cac-b164-b754151e54f6"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Chromatopsia </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">20 (1.2) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (0.4) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                              <tr ID="id_32c8b51d-2bf0-4054-ba57-60ef0c4668ca"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Body as a Whole </content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_b4be55ae-27c6-458a-bbfb-ad48b6055c90"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Fever </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">94 (5.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (1.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">25 (13.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">5 (3.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                              <tr ID="id_79a05d50-2942-4eb8-b29d-fcb90118c1dc"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Chills </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">61 (3.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.2) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">36 (19.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (6.1) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                              <tr ID="id_a34ac066-88a2-4be2-96fa-84edaa65f224"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Headache </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">49 (3) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">9 (1.9) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (4.3) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                              </tr><BR>                              <tr ID="id_b24fc1de-c489-40fb-89db-5c721bbccafa"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Cardiovascular <content styleCode="bold">System</content><BR>                                       </content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_4010dfe0-8d60-432b-9cdf-49d6a80d593e"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Tachycardia </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">39 (2.4) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (1.3) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">5 (2.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                              <tr ID="id_31ce56a6-2e84-4c0c-a998-cf7abb81f0c0"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Digestive System </content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_e2faf643-85b1-4c33-a3b4-48014cb9d7a3"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Nausea </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">89 (5.4) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">18 (3.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">29 (15.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">3 (1.6) </td><BR>                              </tr><BR>                              <tr ID="id_a87479aa-3e9a-44b9-8e6a-893a30250aca"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Vomiting </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">72 (4.4) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">15 (3.2) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">18 (9.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                              </tr><BR>                              <tr ID="id_b662781c-ab1e-4437-8dc1-434d0e9b3a75"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Liver function tests abnormal </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">45 (2.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">15 (3.2) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">4 (2.2) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (3) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1) </td><BR>                              </tr><BR>                              <tr ID="id_d00fa8d3-affa-4bef-a4c1-b67e3e6990fa"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Cholestatic jaundice </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">17 (1) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (1.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">3 (1.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                              <tr ID="id_13d84d80-60e9-4ce9-8ffc-060157e0d2b3"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Metabolic and Nutritional Systems </content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_358f852b-23ed-42f6-9cbb-c7b42bfc4da3"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph>Alkaline phosphatase increased </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">59 (3.6) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">19 (4.1) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">4 (2.2) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">3 (2.3) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">10 (5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">3 (1.6) </td><BR>                              </tr><BR>                              <tr ID="id_c21286c4-d042-494c-abc5-41151733194e"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Hepatic enzymes increased </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">30 (1.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">11 (2.4) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">5 (2.7) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">3 (1.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                              <tr ID="id_8304e1d9-bb7c-43b5-a74c-97ae3fa58bbf"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">SGOT increased </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">31 (1.9) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">9 (1.9) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (4) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1) </td><BR>                              </tr><BR>                              <tr ID="id_aaadcabc-1550-4277-a954-690db2778913"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">SGPT increased </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">29 (1.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">9 (1.9) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (3) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1) </td><BR>                              </tr><BR>                              <tr ID="id_bdc86dfb-c8b0-49e3-9abf-425ff74701f2"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Hypokalemia </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">26 (1.6) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">3 (0.6) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">36 (19.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">16 (12.2) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                              <tr ID="id_b5691082-7e10-42c3-85a9-754b4200481b"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Bilirubinemia </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">15 (0.9) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">5 (1.1) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">3 (1.6) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                              <tr ID="id_05643369-d28e-48d0-affa-988f4d8d1ee7"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Creatinine increased </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">4 (0.2) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">59 (31.9) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">10 (7.6) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                              <tr ID="id_77522406-b27a-4dc2-b1b0-4fe00370f67c"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Nervous System </content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_d4ac91c4-908e-4996-a213-06670ea906d9"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Hallucinations </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">39 (2.4) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">13 (2.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                              <tr ID="id_ff9feec6-6976-4746-8991-f6585c071865"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Skin and Appendages </content><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_8652ecf1-a6dd-427e-bd05-87d374f69a02"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Rash </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">88 (5.3) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">20 (4.3) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">7 (3.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.8) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">3 (1.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                              </tr><BR>                              <tr ID="id_5272ba36-a23f-48b4-b138-e72adb8c2b1f"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Urogenital </content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr ID="id_2426fe4b-6d1b-42c3-8674-74ecdfd279ad"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Kidney function abnormal </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">10 (0.6) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (1.3) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">40 (21.6) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">9 (6.9) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.5) </td><BR>                              </tr><BR>                              <tr ID="id_205d1185-e7d9-4355-83a6-431bf6a68c55"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Acute kidney failure </td><BR>                                 <td align="center" valign="top" styleCode="Rrule">7 (0.4) </td><BR>                                 <td align="center" valign="top" styleCode="Rrule">2 (0.4) </td><BR>                                 <td align="center" valign="top" styleCode="Rrule">11 (5.9) </td><BR>                                 <td align="center" valign="top" styleCode="Rrule">7 (5.3) </td><BR>                                 <td align="center" valign="top" styleCode="Rrule">0 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Visual Disturbances<BR>                           <BR>                              Voriconazole treatment-related visual disturbances are common. In therapeutic trials, approximately 21% of patients experienced abnormal vision, color vision change and/or photophobia. Visual disturbances may be associated with higher plasma concentrations and/or doses.<BR>                              There have been post-marketing reports of prolonged visual adverse events, including optic neuritis and papilledema [see Warnings and Precautions (5.3)<BR>                                 ].<BR>                              The mechanism of action of the visual disturbance is unknown, although the site of action is most likely to be within the retina. In a study in healthy subjects investigating the effect of 28-day treatment with voriconazole on retinal function, voriconazole caused a decrease in the electroretinogram (ERG) waveform amplitude, a decrease in the visual field and an alteration in color perception. The ERG measures electrical currents in the retina. The effects were noted early in administration of voriconazole and continued through the course of study drug dosing. Fourteen days after end of dosing, ERG, visual fields and color perception returned to normal [see Warnings an Precautions (5)<BR>                                 ].<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Dermatological Reactions<BR>                           <BR>                              Dermatological reactions were common in the patients treated with voriconazole. The mechanism underlying these dermatologic adverse events remains unknown.<BR>                              Serious cutaneous reactions, including Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme have been reported during treatment with voriconazole. If a patient develops an exfoliative cutaneous reaction, voriconazole should be discontinued.<BR>                              In addition, voriconazole has been associated with photosensitivity skin reactions. Patients should avoid strong, direct sunlight during voriconazole therapy. In patients with photosensitivity skin reactions, squamous cell carcinoma of the skin and melanoma have been reported during long-term therapy. If a patient develops a skin lesion consistent with squamous cell carcinoma or melanoma, voriconazole should be discontinued [see Warnings and Precautions (5.13)<BR>                                 ].<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Less Common Adverse Events<BR>                           <BR>                              The following adverse events occurred in < 2% of all voriconazole-treated patients in all therapeutic studies (n = 1,655). This listing includes events where a causal relationship to voriconazole cannot be ruled out or those which may help the physician in managing the risks to the patients. The list does not include events included in Table 2 above and does not include every event reported in the voriconazole clinical program.<BR>                              <BR>                                 Body as a Whole: abdominal pain, abdomen enlarged, allergic reaction, anaphylactoid reaction [see Warnings and Precautions (5.6)<BR>                                 ], ascites, asthenia, back pain, chest pain, cellulitis, edema, face edema, flank pain, flu syndrome, graft versus host reaction, granuloma, infection, bacterial infection, fungal infection, injection site pain, injection site infection/inflammation, mucous membrane disorder, multi-organ failure, pain, pelvic pain, peritonitis, sepsis, substernal chest pain<BR>                              <BR>                                 Cardiovascular: atrial arrhythmia, atrial fibrillation, AV block complete, bigeminy, bradycardia, bundle branch block, cardiomegaly, cardiomyopathy, cerebral hemorrhage, cerebral ischemia, cerebrovascular accident, congestive heart failure, deep thrombophlebitis, endocarditis, extrasystoles, heart arrest, hypertension, hypotension, myocardial infarction, nodal arrhythmia, palpitation, phlebitis, postural hypotension, pulmonary embolus, QT interval prolonged, supraventricular extrasystoles, supraventricular tachycardia, syncope, thrombophlebitis, vasodilatation, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia (including torsade de pointes) [see Warnings and Precautions (5.6)<BR>                                 ].<BR>                              <BR>                                 Digestive: anorexia, cheilitis, cholecystitis, cholelithiasis, constipation, diarrhea, duodenal ulcer perforation, duodenitis, dyspepsia, dysphagia, dry mouth, esophageal ulcer, esophagitis, flatulence, gastroenteritis, gastrointestinal hemorrhage, GGT/LDH elevated, gingivitis, glossitis, gum hemorrhage, gum hyperplasia, hematemesis, hepatic coma, hepatic failure, hepatitis, intestinal perforation, intestinal ulcer, jaundice, enlarged liver, melena, mouth ulceration, pancreatitis, parotid gland enlargement, periodontitis, proctitis, pseudomembranous colitis, rectal disorder, rectal hemorrhage, stomach ulcer, stomatitis, tongue edema<BR>                              <BR>                                 Endocrine: adrenal cortex insufficiency, diabetes insipidus, hyperthyroidism, hypothyroidism<BR>                              <BR>                                 Hemic and Lymphatic: agranulocytosis, anemia (macrocytic, megaloblastic, microcytic, normocytic), aplastic anemia, hemolytic anemia, bleeding time increased, cyanosis, DIC, ecchymosis, eosinophilia, hypervolemia, leukopenia, lymphadenopathy, lymphangitis, marrow depression, pancytopenia, petechia, purpura, enlarged spleen, thrombocytopenia, thrombotic thrombocytopenic purpura<BR>                              <BR>                                 Metabolic and Nutritional: albuminuria, BUN increased, creatine phosphokinase increased, edema, glucose tolerance decreased, hypercalcemia, hypercholesteremia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hyperuricemia, hypocalcemia, hypoglycemia, hypomagnesemia, hyponatremia, hypophosphatemia, peripheral edema, uremia<BR>                              <BR>                                 Musculoskeletal: arthralgia, arthritis, bone necrosis, bone pain, leg cramps, myalgia, myasthenia, myopathy, osteomalacia, osteoporosis<BR>                              <BR>                                 Nervous System: abnormal dreams, acute brain syndrome, agitation, akathisia, amnesia, anxiety, ataxia, brain edema, coma, confusion, convulsion, delirium, dementia, depersonalization, depression, diplopia, dizziness, encephalitis, encephalopathy, euphoria, Extrapyramidal Syndrome, grand mal convulsion, Guillain-Barré syndrome, hypertonia, hypesthesia, insomnia, intracranial hypertension, libido decreased, neuralgia, neuropathy, nystagmus, oculogyric<BR>                              crisis, paresthesia, psychosis, somnolence, suicidal ideation, tremor, vertigo<BR>                              <BR>                                 Respiratory System: cough increased, dyspnea, epistaxis, hemoptysis, hypoxia, lung edema, pharyngitis, pleural effusion, pneumonia, respiratory disorder, respiratory distress syndrome, respiratory tract infection, rhinitis, sinusitis, voice alteration<BR>                              <BR>                                 Skin and Appendages: alopecia, angioedema, contact dermatitis, discoid lupus erythematosis, eczema, erythema multiforme, exfoliative dermatitis, fixed drug eruption, furunculosis, herpes simplex, maculopapular rash, melanoma, melanosis, photosensitivity skin reaction, pruritus, pseudoporphyria, psoriasis, skin discoloration, skin disorder, skin dry, Stevens-Johnson syndrome, squamous cell carcinoma, sweating, toxic epidermal necrolysis, urticaria<BR>                              <BR>                                 Special Senses: abnormality of accommodation, blepharitis, color blindness, conjunctivitis, corneal opacity, deafness, ear pain, eye pain, eye hemorrhage, dry eyes, hypoacusis, keratitis, keratoconjunctivitis, mydriasis, night blindness, optic atrophy, optic neuritis, otitis externa, papilledema, retinal hemorrhage, retinitis, scleritis, taste loss, taste perversion, tinnitus, uveitis, visual field defect<BR>                              <BR>                                 Urogenital: anuria, blighted ovum, creatinine clearance decreased, dysmenorrhea, dysuria, epididymitis, glycosuria, hemorrhagic cystitis, hematuria, hydronephrosis, impotence, kidney pain, kidney tubular necrosis, metrorrhagia, nephritis, nephrosis, oliguria, scrotal edema, urinary incontinence, urinary retention, urinary tract infection, uterine hemorrhage, vaginal hemorrhage<BR>                           <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.3 Clinical Laboratory Values<BR>                     <BR>                        The overall incidence of clinically significant transaminase abnormalities in all therapeutic studies was 12.4% (206/1,655) of patients treated with voriconazole. Increased incidence of liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of abnormal liver function tests either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.<BR>                        Voriconazole has been infrequently associated with cases of serious hepatic toxicity including cases of jaundice and rare cases of hepatitis and hepatic failure leading to death. Most of these patients had other serious underlying conditions.<BR>                        Liver function tests should be evaluated at the start of and during the course of voriconazole therapy. Patients who develop abnormal liver function tests during voriconazole therapy should be monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). Discontinuation of voriconazole must be considered if clinical signs and symptoms consistent with liver disease develop that may be attributable to voriconazole [see Warnings and Precautions (5.2)<BR>                           ].<BR>                        Acute renal failure has been observed in severely ill patients undergoing treatment with voriconazole. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medications and have concurrent conditions that may result in decreased renal function. It is recommended that patients are monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.<BR>                        Tables 3 to 5 show the number of patients with hypokalemia and clinically significant changes in renal and liver function tests in three randomized, comparative multicenter studies. In study 305, patients with esophageal candidiasis were randomized to either oral voriconazole or oral fluconazole. In study 307/602, patients with definite or probable invasive aspergillosis were randomized to either voriconazole or amphotericin B therapy. In study 608, patients with candidemia were randomized to either voriconazole or the regimen of amphotericin B followed by fluconazole.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="734.000" ID="id_899c12a2-4c6e-4550-b51a-08fbd7026f2b"><BR>                           <caption ID="id_37d89933-4b6b-403a-b478-135eda0f0c43">Table 3. Protocol 305- Patients with Esophageal Candidiasis Clinically Significant Laboratory Test Abnormalities</caption><BR>                           <col width="25.6%"/><BR>                           <col width="24.4%"/><BR>                           <col width="25.6%"/><BR>                           <col width="24.4%"/><BR>                           <tfoot ID="id_172c9551-242d-4d26-9423-af576d586ad6"><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="4" styleCode="Lrule Botrule Rrule">n &#160;&#160;&#160;&#160;number of patients with a clinically significant abnormality while on study therapy <br/>N&#160;&#160;&#160;&#160; total number of patients with at least one observation of the given lab test while on study therapy <br/>ULN&#160;&#160;&#160;&#160;&#160; upper limit of normal</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr ID="id_bc4cd85b-e01b-42b3-8f2e-1ba7b17c78bb"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">Criteria<footnote ID="id-b8273740-e1f0-461e-a7c9-92d8f17ca6e8">Without regard to baseline value</footnote><BR>                                 </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">Voriconazole </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">Fluconazole </td><BR>                              </tr><BR>                              <tr ID="id_d03fa36d-0a34-4366-ae65-d7865937c90b"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">n/N (%) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">n /N (%) </td><BR>                              </tr><BR>                              <tr ID="id_3dd78bf9-3443-41d9-865b-06c4c826c171"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">T. Bilirubin </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 1.5 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">8/185 (4.3) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">7/186 (3.8) </td><BR>                              </tr><BR>                              <tr ID="id_136d9344-f668-4abf-8371-f639a6ad208c"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">AST </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">38/187 (20.3) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">15/186 (8.1) </td><BR>                              </tr><BR>                              <tr ID="id_1695e322-4f5a-406e-a2fc-f8d096800a00"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">ALT </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">20/187 (10.7) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">12/186 (6.5) </td><BR>                              </tr><BR>                              <tr ID="id_8a31f159-0589-4ace-ad46-1af7ef38317c"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">Alk phos </td><BR>                                 <td align="center" valign="middle" styleCode="Rrule">&gt; 3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Rrule">19/187 (10.2) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">14/186 (7.5) </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="725.000" ID="id_6006d8aa-16d2-4109-92c8-58b6245f458e"><BR>                           <caption ID="id_a67cd1c0-7e0f-4166-a488-35493fb6cab1">Table 4. Protocol 307/602- Primary Treatment of Invasive Aspergillosis Clinically Significant Laboratory Test Abnormalities</caption><BR>                           <col width="24.7%"/><BR>                           <col width="24.7%"/><BR>                           <col width="25.9%"/><BR>                           <col width="24.7%"/><BR>                           <tfoot ID="id_e6c1afe9-2b49-42ee-96f4-fca09fdea689"><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="4" styleCode="Lrule Botrule Rrule">n&#160;&#160;&#160;&#160;&#160; number of patients with a clinically significant abnormality while on study therapy <br/>N&#160;&#160;&#160;&#160;&#160; total number of patients with at least one observation of the given lab test while on study therapy<br/>ULN&#160;&#160;&#160;&#160;&#160; upper limit of normal <br/>LLN&#160;&#160;&#160;&#160;&#160; lower limit of normal</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr ID="id_6f7de87c-608b-47ca-b1fa-d8d1d71f3407"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">Criteria<footnote ID="id-0989d865-1bfd-4149-8aaf-0434760cdaff">Without regard to baseline value</footnote><BR>                                 </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">Voriconazole </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">Amphotericin B<footnote ID="id-1305ea4a-4fbe-45fd-9682-59e20ad1609f">Amphotericin B followed by other licensed antifungal therapy</footnote><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_cc1a3f0c-9b5c-40ba-bbf2-d378075b86e5"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">n/N (%) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">n/N (%) </td><BR>                              </tr><BR>                              <tr ID="id_1e577a57-b0aa-488c-83ff-61d67a382d0c"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">T. Bilirubin </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 1.5 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">35/180 (19.4) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">46/173 (26.6) </td><BR>                              </tr><BR>                              <tr ID="id_41b7b756-98cb-492a-a0e0-22fc5f67b18b"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">AST </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">21/180 (11.7) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">18/174 (10.3) </td><BR>                              </tr><BR>                              <tr ID="id_d5e6cf8e-2c03-4e31-a362-fd768668fc6f"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">ALT </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">34/180 (18.9) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">40/173 (23.1) </td><BR>                              </tr><BR>                              <tr ID="id_bc9dea6f-7851-4fed-813c-78a8f0352617"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">Alk phos </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">29/181 (16) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">38/173 (22) </td><BR>                              </tr><BR>                              <tr ID="id_0e9646bc-9240-43b2-b40b-46acaaa2f2da"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">Creatinine </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 1.3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">39/182 (21.4) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">102/177 (57.6) </td><BR>                              </tr><BR>                              <tr ID="id_84e813ff-2e5e-4336-9753-6b418ca86b68"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">Potassium </td><BR>                                 <td align="center" valign="middle" styleCode="Rrule">&lt; 0.9 x LLN </td><BR>                                 <td align="center" valign="middle" styleCode="Rrule">30/181 (16.6) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">70/178 (39.3) </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="717.000" ID="id_303bdf5b-b195-478d-ae33-7311bcd1b73d"><BR>                           <caption ID="id_341292e7-60f3-42cb-a08e-dd03a5ca3c58">Table 5. Protocol 608- Treatment of Candidemia Clinically Significant Laboratory Test Abnormalities</caption><BR>                           <col width="23.8%"/><BR>                           <col width="25.0%"/><BR>                           <col width="26.2%"/><BR>                           <col width="25.0%"/><BR>                           <tfoot ID="id_2b6b1b8b-cf4b-4a8a-ada6-91975152d9f5"><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="4" styleCode="Lrule Botrule Rrule">n &#160;&#160;&#160;&#160;&#160;number of patients with a clinically significant abnormality while on study therapy <br/>N&#160;&#160;&#160;&#160;&#160; total number of patients with at least one observation of the given lab test while on study therapy<br/>ULN&#160;&#160;&#160;&#160;&#160; upper limit of normal <br/>LLN&#160;&#160;&#160;&#160;&#160; lower limit of normal</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr ID="id_5953dc64-a97a-47e5-aba8-9c1cf85bfede"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">Criteria<footnote ID="id-c2f4ccd9-3d57-466d-93f1-3b196a94be98">Without regard to baseline value</footnote><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">Voriconazole </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>Amphotericin B </paragraph><BR>                                    <paragraph>followed by </paragraph>Fluconazole </td><BR>                              </tr><BR>                              <tr ID="id_325f543f-fa22-4fa9-b6c6-6c689fd142a9"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"/><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule"/><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">n/N (%) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">n/N (%) </td><BR>                              </tr><BR>                              <tr ID="id_f12b3dc4-fc0b-4870-9098-41516f890ca6"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">T. Bilirubin </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 1.5 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">50/261 (19.2) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">31/115 (27) </td><BR>                              </tr><BR>                              <tr ID="id_531c5502-435c-4fcc-9fc6-4d5f1a5c6801"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">AST </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">40/261 (15.3) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">16/116 (13.8) </td><BR>                              </tr><BR>                              <tr ID="id_00504553-1d02-4e1e-90e9-a2649340a275"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">ALT </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">22/261 (8.4) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">15/116 (12.9) </td><BR>                              </tr><BR>                              <tr ID="id_54fc4bbd-7448-4444-8c0f-5713797c9f48"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">Alk phos </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">59/261 (22.6) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">26/115 (22.6) </td><BR>                              </tr><BR>                              <tr ID="id_5926dffe-b6b6-46c1-99e2-b81c48bd6102"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">Creatinine </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt; 1.3 x ULN </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">39/260 (15) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">32/118 (27.1) </td><BR>                              </tr><BR>                              <tr ID="id_770c0f8e-d25e-43c1-9495-6bfa06565934"><BR>                                 <td align="left" valign="middle" styleCode="Lrule Botrule Rrule">Potassium </td><BR>                                 <td align="center" valign="middle" styleCode="Rrule">&lt; 0.9 x LLN </td><BR>                                 <td align="center" valign="middle" styleCode="Rrule">43/258 (16.7) </td><BR>                                 <td align="center" valign="middle" styleCode="Botrule Rrule">35/118 (29.7) </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.4 Post-Marketing Experience<BR>                     <BR>                        The following adverse reactions have been identified during post approval use of voriconazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. <BR>                     <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Skeletal<BR>                           <BR>                              Fluorosis and periostitis have been reported during long-term voriconazole therapy [see Warnings and Precautions (5.14)<BR>                                 ].<BR>                           <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>